Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRT-402 in Refractory Autoimmune Disease
NCT07778446Phase 2Recruiting
- Sponsor
- Myeloid Therapeutics
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of CRT-402 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), sponsored by Myeloid Therapeutics. Started Aug 2026; status: recruiting.
02
Drugs
CRT-402
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07778446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07778446.